RxDoctor Payments Data

Ruben Saavedra, PA

Physician Assistant · Deer Park, NYNPI 1942726294

Payments from drug & device makers

$23,683in general payments, 2019–2025

Across 936 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$2K
  • SK Life Science, Inc.$2K
  • Neurocrine Biosciences, Inc.$2K
  • UCB, Inc.$1K
  • Neurelis, Inc.$1K
  • plus $12K from 43 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$23,574100%
  • Education$940%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,683 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$83,133
Medicare patients
527
Services billed
935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate185$274,093
UbrelvyUbrogepant125$203,214
ZtlidoLidocaine320$129,547
QuliptaAtogepant86$93,981
OngentysOpicapone94$67,593
BotoxOnabotulinumtoxina58$63,436
Emgality PenGalcanezumab-Gnlm60$40,324
Doxepin Hcl310$38,133
RexultiBrexpiprazole16$22,215
Aimovig AutoinjectorErenumab-Aooe24$17,038
Diclofenac Sodium ErDiclofenac Sodium106$8,325
FycompaPerampanel12$7,416
Memantine Hcl770$7,328
Lidocaine26$6,391
Memantine Hcl ErMemantine Hcl75$5,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$4,091$360,631269 claims
PfizerNurtec Odt$871$274,093185 claims
Scilex Pharmaceuticals Inc.Ztlido$794$129,547320 claims
Neurocrine Biosciences, Inc.Ongentys$1,587$67,59394 claims
Otsuka America Pharmaceutical, Inc.Rexulti$277$22,21516 claims
Eisai Inc.Fycompa$1,079$7,41612 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$385$1,39126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Deer Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →